Page 15 - Double Blind Study News Today

A new analysis found that patients with multiple myeloma receiving standard therapies have much worse outcomes compared with those treated in clinical trials.

An exploratory analysis reveals potential associations between a dietary intervention and both a reduction in postmenopausal vasomotor symptoms and changes in the gut microbiome.

Benefits of genetic testing in adults with unexplained epilepsy include enrollment in a clinical trial of a relevant gene therapy, connection to families with a similar diagnosis, and peace of mind.

Demand for a diabetes medicine called Ozempic is soaring as people take it to shed pounds, leading to shortages in countries including Britain, Germany, Belgium and the United States.

The U.S. health regulators staff on Wednesday flagged concerns that data on Mercks chronic cough drug might not be enough to prove the treatments meaningful benefit.

The US Senate on Tuesday voted to confirm President Joe Bidens pick to run the National Institutes of Health, Monica Bertagnolli.

Pfizer on Wednesday said it will set the US price for its COVID-19 antiviral treatment Paxlovid at nearly $1400 per five-day course when it moves to commercial sales after government stocks run out, more than double what the government currently pays for it.

In practice, patients may not lose as much weight with semaglutide as the clinical trials suggest, depending on individual factors.

The National Institutes of Health has begun an early stage study on its experimental vaccine targeting six strains of influenza virus.

Contract research firm ICON said on Wednesday it is partnering with the US government for a clinical trial to test the effectiveness of next generation COVID-19 vaccine candidates.